Myfortic Mechanism:inhibits lymphocyde purine synthesis by reversibly and noncompetively inhibiting the enzyme inosine monophosphate dehydrogenase (IMPDH). IMPDH is an important enzyme in the de novo synthesis of purines and is the rate-limiting step in converting inosine monophosphate (IMP) to guanosine monophosphate (GMP), an important intermediate in the synthesis of lymphocyte DNA, RNA, proteins, and glycoproteins. Lymphocytes
Uses 1- For the prevention of—renal allograft rejection in combination with cyclosporine and corticosteroids 2- For the treatment of rheumatoid arthritis
Dosage: 400 mg in daily in chronic phase & 600 mg daily in accelerated phase.
Tablets
210 EGP
Myfortic Mechanism:inhibits lymphocyde purine synthesis by reversibly and noncompetively inhibiting the enzyme inosine monophosphate dehydrogenase (IMPDH). IMPDH is an important enzyme in the de novo synthesis of purines and is the rate-limiting step in converting inosine monophosphate (IMP) to guanosine monophosphate (GMP), an important intermediate in the synthesis of lymphocyte DNA, RNA, proteins, and glycoproteins. Lymphocytes
Uses 1- For the prevention of—renal allograft rejection in combination with cyclosporine and corticosteroids 2- For the treatment of rheumatoid arthritis
Dosage: 400 mg in daily in chronic phase & 600 mg daily in accelerated phase.
Note: All the provided information about this drug does not substitute for consulting a doctor.